3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Classical hematology
1
Conditions
Prostatic Neoplasms
9
Neoplasms
3
Venous Thromboembolism
1
Urinary Bladder Neoplasms
1
Testicular Neoplasms
1
Recurrence
1
Neoplasms, Germ Cell and Embryonal
1
Hematuria
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Interventions
Etoposide
30
Carboplatin
30
Cisplatin
23
Ifosfamide
22
Filgrastim
22
Paclitaxel
18
Peripheral Blood Stem Cell Transplantation
16
Bleomycin
13
Cyclophosphamide
11
Radiotherapy
8
Thiotepa
7
Magnetic Resonance Spectroscopy
6
Gemcitabine
6
pegfilgrastim
5
Therapeutics
5
Polymerase Chain Reaction
5
Melphalan
5
Granulocyte Colony-Stimulating Factor
5
Flow Cytometry
5
Busulfan
5
etoposide phosphate
4
Temozolomide
4
Psychiatric Rehabilitation
4
Oxaliplatin
4
Dexamethasone
4
sargramostim
3
Vinblastine
3
Taxes
3
Surveys and Questionnaires
3
Methylprednisolone
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Testicular Neoplasms
×
Aspirin
×
Genitourinary
×
Clear all
NCT06866964
2026-02-02
ASPIRE
Wake Forest University Health Sciences
Phase 2
Recruiting
35 enrolled